Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2011 4
2012 14
2013 11
2014 11
2015 26
2016 60
2017 63
2018 54
2019 32
2020 67
2021 49
2022 34
2023 35
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

412 results

Results by year

Filters applied: . Clear all
Page 1
Elotuzumab for multiple myeloma.
[No authors listed] [No authors listed] Aust Prescr. 2022 Aug;45(4):138-139. doi: 10.18773/austprescr.2022.040. Epub 2022 Jul 7. Aust Prescr. 2022. PMID: 36110178 Free PMC article. Review. No abstract available.
Elotuzumab in multiple myeloma.
Bruzzese A, Martino EA, Vigna E, Iaccino E, Mendicino F, Lucia E, Olivito V, Filippelli G, Neri A, Morabito F, Gentile M. Bruzzese A, et al. Expert Opin Biol Ther. 2023 Jan;23(1):7-10. doi: 10.1080/14712598.2022.2145882. Epub 2022 Nov 14. Expert Opin Biol Ther. 2023. PMID: 36373842 No abstract available.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Lonial S, et al. N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2. N Engl J Med. 2015. PMID: 26035255 Free article. Clinical Trial.
BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple …
BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), sho …
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Dimopoulos MA, et al. N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762. N Engl J Med. 2018. PMID: 30403938 Clinical Trial.
BACKGROUND: The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. ...METHODS: Patients with multiple myeloma that was ref …
BACKGROUND: The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective i …
Elotuzumab as a novel anti-myeloma immunotherapy.
Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D. Radhakrishnan SV, et al. Hum Vaccin Immunother. 2017 Aug 3;13(8):1751-1757. doi: 10.1080/21645515.2017.1327487. Epub 2017 Jun 12. Hum Vaccin Immunother. 2017. PMID: 28604269 Free PMC article. Review.
Here we review the preclinical investigations that led to the development of elotuzumab and the clinical studies that resulted in its approval for the treatment of relapsed/refractory multiple myeloma. Although preclinical data looked very promising, elotu …
Here we review the preclinical investigations that led to the development of elotuzumab and the clinical studies that resulted in its …
Emerging immunotherapies in multiple myeloma.
Shah UA, Mailankody S. Shah UA, et al. BMJ. 2020 Sep 21;370:m3176. doi: 10.1136/bmj.m3176. BMJ. 2020. PMID: 32958461 Review.
The first immunotherapy used to treat hematologic cancers, including multiple myeloma, was an allogeneic stem cell transplant. In the mid-2000s, immunomodulatory drugs thalidomide, lenalidomide, and subsequently pomalidomide were proven to be effective in multipl …
The first immunotherapy used to treat hematologic cancers, including multiple myeloma, was an allogeneic stem cell transplant. …
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. Dimopoulos MA, et al. J Clin Oncol. 2023 Jan 20;41(3):568-578. doi: 10.1200/JCO.21.02815. Epub 2022 Aug 12. J Clin Oncol. 2023. PMID: 35960908 Free PMC article. Clinical Trial.
PURPOSE: In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132), elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved progression-free survival (PFS) versus pomalidomide/dexamethasone (Pd) in patients with relapsed/refract …
PURPOSE: In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132), elotuzumab combined with pomalidomide/dexamet …
Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Lamb YN. Lamb YN. Drugs. 2018 Sep;78(14):1481-1488. doi: 10.1007/s40265-018-0969-4. Drugs. 2018. PMID: 30232695 Review.
Intravenous elotuzumab (Empliciti), a monoclonal antibody targeting the signalling lymphocytic activation molecule F7 (SLAMF7) glycoprotein, is approved for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in previo …
Intravenous elotuzumab (Empliciti), a monoclonal antibody targeting the signalling lymphocytic activation molecule F7 (SLAMF7) glycop …
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date.
Weisel K. Weisel K. Onco Targets Ther. 2016 Oct 5;9:6037-6048. doi: 10.2147/OTT.S94531. eCollection 2016. Onco Targets Ther. 2016. PMID: 27785050 Free PMC article. Review.
In several nonclinical models of multiple myeloma, elotuzumab was effective as a single agent and in combination with standard myeloma treatments, supporting the use of elotuzumab in patients. ...This review summarizes the nonclinical and clinic …
In several nonclinical models of multiple myeloma, elotuzumab was effective as a single agent and in combination with s …
Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab.
Einsele H, Schreder M. Einsele H, et al. Ther Adv Hematol. 2016 Oct;7(5):288-301. doi: 10.1177/2040620716657993. Epub 2016 Jul 15. Ther Adv Hematol. 2016. PMID: 27695618 Free PMC article. Review.
In combination with lenalidomide and low-dose dexamethasone, elotuzumab has shown remarkable effects in patients with relapsed or refractory multiple myeloma. ...This review discusses the use of elotuzumab as an antimultiple myeloma agent and pr …
In combination with lenalidomide and low-dose dexamethasone, elotuzumab has shown remarkable effects in patients with relapsed or ref …
412 results

Searches related to "myeloma elotuzumab"